$IMMP has been discussed by 2 distinct FinTwit voices over the past 12 months, accumulating 5 mentions between March 13, 2026 and April 20, 2026. @jacobplieth (Jacob Plieth) is the most active voice covering the biotech stock, contributing 4 mentions, while @acinvestorblog (Antonio Costa) contributed 1 mention. The ticker was first mentioned on March 13, 2026, with discussion centered around clinical trial outcomes and technical levels.

Discussion of $IMMP has touched on phase 3 trial results and stock performance metrics. @jacobplieth noted on March 13 that lung cancer was the appropriate indication pursued in phase 3, while also noting significant stock decline. More recent commentary from @acinvestorblog on April 20 highlighted technical analysis, referencing a specific price level as a breakout watch point.